{"id":"latanoprost","rwe":[{"pmid":"41890785","year":"2026","title":"Using selective laser trabeculoplasty to manage glaucoma in a child with phakomatosis pigmentovascularis.","finding":"","journal":"American journal of ophthalmology case reports","studyType":"Clinical Study"},{"pmid":"41883732","year":"2026","title":"Preclinical Evaluation of Safety and Efficacy of QLS-111: A Novel Formulation of an Adenosine Triphosphate-Sensitive Potassium Channel Opener.","finding":"","journal":"Ophthalmology science","studyType":"Clinical Study"},{"pmid":"41868229","year":"2026","title":"Sustained intraocular pressure lowering from suprachoroidal injection of a latanoprost lipid nanoparticle delivery system in the rabbit.","finding":"","journal":"Frontiers in medicine","studyType":"Clinical Study"},{"pmid":"41842582","year":"2026","title":"Efficacy and Safety of Preservative-Free versus Preserved Latanoprost in Glaucoma and Ocular Hypertension: A Systematic Review and Meta-analysis.","finding":"","journal":"Journal of glaucoma","studyType":"Clinical Study"},{"pmid":"41794792","year":"2026","title":"Mitochondria transplantation reduces intraocular pressure by improving mitochondrial function and remodeling trabecular meshwork.","finding":"","journal":"Journal of translational medicine","studyType":"Clinical Study"}],"_fda":{"id":"c63757a2-c757-4098-a29d-7a94104d050f","set_id":"113abcc6-6e5c-4a57-ad6a-d69508ee990e","openfda":{"nui":["N0000175454","M0017805"],"unii":["6Z5B6HVF6O"],"route":["OPHTHALMIC"],"rxcui":["314072"],"spl_id":["c63757a2-c757-4098-a29d-7a94104d050f"],"brand_name":["latanoprost"],"spl_set_id":["113abcc6-6e5c-4a57-ad6a-d69508ee990e"],"package_ndc":["68083-609-01"],"product_ndc":["68083-609"],"generic_name":["LATANOPROST"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Prostaglandins [CS]"],"substance_name":["LATANOPROST"],"pharm_class_epc":["Prostaglandin Analog [EPC]"],"manufacturer_name":["Gland Pharma Limited"],"application_number":["ANDA218257"],"is_original_packager":[true]},"version":"5","pregnancy":["8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of latanoprost ophthalmic solution administration in pregnant women.to inform drug-associated risks. In animal reproduction studies, intravenous (IV) administration of latanoprost to pregnant rabbits and rats throughout the period of organogenesis produced malformations, embryofetal lethality and spontaneous abortion at clinically relevant doses [see Data] . The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20% of clinically recognized pregnancies. Data Animal Data Embryofetal studies were conducted in pregnant rabbits administered latanoprost daily by IV injection on gestation days 6 through 18, to target the period of organogenesis. A no observed adverse effect level (NOAEL) was not established for rabbit developmental toxicity. Post-implantation loss due to late resorption was shown as doses ≥0.2 mcg/kg/day (equivalent to 1.3 times the maximum recommended human ophthalmic dose [RHOD], on a mg/m 2 basis, assuming 100% absorption). Spina bifida and abortion occurred at 5 mcg/kg/day (equivalent to 32 times the maximum RHOD). Total litter loss due to early resorption was observed at doses ≥50 mcg/kg/day (324 times the maximum RHOD). Transient signs of maternal toxicity were observed after IV dosing (increased breathing, muscle tremors, slight motor incoordination) at 300 mcg/kg/day (1946 times the maximum RHOD). No maternal toxicity was observed at doses up to 50 mcg/kg/day. Embryofetal studies were conducted in pregnant rats administered latanoprost daily by IV injection on gestation days 6 through 15, to target the period of organogenesis. A NOAEL for rat developmental toxicity was not established. Cleft palate was observed at 1 mcg/kg (equivalent to 3.2 times the maximum RHOD, on a mg/m 2 basis, assuming 100% absorption). Brain porencephalic cyst(s) were observed ≥50 mcg/kg (162 times the maximum RHOD). Skeletal anomalies were observed at 250 mcg/kg (811 times the maximum RHOD). No maternal toxicity was detectable at 250 mcg/kg/day. Prenatal and postnatal development was assessed in rats. Pregnant rats were administered latanoprost daily by IV injection from gestation day 15, through delivery, until weaning (lactation Day 21). No adverse effects on rat offspring were observed at doses up to 10 mcg/kg/day (32 times the maximum RHOD, on a mg/m 2 basis, assuming 100% absorption). At 100 mcg/kg/day (324 times the maximum RHOD), maternal deaths and pup mortality occurred."],"overdosage":["10 OVERDOSAGE IV infusion of up to 3 mcg/kg of latanoprost in healthy volunteers produced mean plasma concentrations 200 times higher than during clinical treatment with latanoprost ophthalmic solution and no adverse reactions were observed. IV dosages of 5.5 to 10 mcg/kg caused abdominal pain, dizziness, fatigue, hot flushes, nausea, and sweating. If overdosage with latanoprost ophthalmic solution occurs, treatment should be symptomatic."],"description":["11 DESCRIPTION Latanoprost is a prostaglandin F 2α analogue. Its chemical name is isopropyl-(Z)-7[(1R,2R,3R,5S)3,5- dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. Its molecular formula is C 26 H 40 O 5 and its chemical structure is: Latanoprost is a colorless to slightly yellow oil that is very soluble in acetonitrile and freely soluble in acetone, ethanol, ethyl acetate, isopropanol, methanol, and octanol. It is practically insoluble in water. Latanoprost ophthalmic solution 0.005% is supplied as a sterile, isotonic, buffered aqueous solution of latanoprost with a pH of approximately 6.7 and an osmolality of approximately 267 mOsmol/kg. Each mL of latanoprost ophthalmic solution contains 50 mcg of latanoprost. Benzalkonium chloride, 0.02% is added as a preservative. The inactive ingredients are: sodium chloride, sodium dihydrogen phosphate monohydrate, Disodium hydrogen phosphate anhydrous, and water for injection. One drop contains approximately 1.5 mcg of latanoprost. latanoprost-spl-structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Latanoprost ophthalmic solution is a clear, isotonic, buffered, preserved colorless solution of latanoprost 50 mcg/mL (0.005%). It is supplied as a 2.5 mL solution in a 5 mL clear low density polyethylene bottle with a clear polyethylene dropper tip, a turquoise high density polyethylene screw cap, and a tamper-evident ring between the bottle and cap. 2.5 mL fill, 50 mcg/mL (0.005%): Package of 1 bottle: NDC 68083-609-01 Storage: Protect from light. Store unopened bottle(s) under refrigeration at 2°C to 8°C (36°F to 46°F). During shipment to the patient, the bottle may be maintained at temperatures up to 40°C (104°F) for a period not exceeding 8 days. Once a bottle is opened for use, it may be stored at room temperature up to 25°C (77°F) for 6 weeks."],"geriatric_use":["8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20241129","clinical_studies":["14 CLINICAL STUDIES 14.1 Elevated Baseline IOP Patients with mean baseline IOP of 24 – 25 mmHg who were treated for 6 months in multi-center, randomized, controlled trials demonstrated 6 – 8 mmHg reductions in IOP. This IOP reduction with latanoprost ophthalmic solution 0.005% dosed once daily was equivalent to the effect of timolol 0.5% dosed twice daily. 14.2 Progression of Increased Iris Pigmentation A 3-year open-label, prospective safety study with a 2-year extension phase was conducted to evaluate the progression of increased iris pigmentation with continuous use of latanoprost ophthalmic solution once-daily as adjunctive therapy in 519 patients with open-angle glaucoma. The analysis was based on observed-cases population of the 380 patients who continued in the extension phase. Results showed that the onset of noticeable increased iris pigmentation occurred within the first year of treatment for the majority of the patients who developed noticeable increased iris pigmentation. Patients continued to show signs of increasing iris pigmentation throughout the 5 years of the study. Observation of increased iris pigmentation did not affect the incidence, nature, or severity of adverse events (other than increased iris pigmentation) recorded in the study. IOP reduction was similar regardless of the development of increased iris pigmentation during the study."],"pharmacodynamics":["12.2 Pharmacodynamics Reduction of the IOP in man starts about 3-4 hours after administration and maximum effect is reached after 8-12 hours. IOP reduction is present for at least 24 hours."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Latanoprost is absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form to become biologically active. Distribution The distribution volume in humans is 0.16 ± 0.02 L/kg. The acid of latanoprost can be measured in aqueous humor during the first 4 hours, and in plasma only during the first hour after local administration. Studies in man indicate that the peak concentration in the aqueous humor is reached about two hours after topical administration. Elimination Metabolism Latanoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to the biologically active acid. The active acid of latanoprost reaching the systemic circulation is primarily metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites via fatty acid β-oxidation. Excretion The elimination of the acid of latanoprost from human plasma is rapid (t 1/2 = 17 min) after both IV and topical administration. Systemic clearance is approximately 7 mL/min/kg. Following hepatic β-oxidation, the metabolites are mainly eliminated via the kidneys. Approximately 88% and 98% of the administered dose are recovered in the urine after topical and IV dosing, respectively."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions were reported in postmarketing experience and are discussed in greater detail in other sections of the label: Iris pigmentation changes [see Warnings and Precautions (5.1) ] Eyelid skin darkening [see Warnings and Precautions (5.1) ] Eyelash changes (increased length, thickness, pigmentation, and number of lashes) [see Warnings and Precautions (5.2) ] Intraocular inflammation (iritis/uveitis) [see Warnings and Precautions (5.3) ] Macular edema, including cystoid macular edema [see Warnings and Precautions (5.4) ] Most common adverse reactions (5-15%) from clinical trials are blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, and punctate keratitis. (6) To report SUSPECTED ADVERSE REACTIONS, contact Gland Pharma Limited at 609-250-7990 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Latanoprost ophthalmic solution was studied in three multicenter, randomized, controlled clinical trials. Patients received 50 mcg/mL latanoprost ophthalmic solution once daily or 5 mg/mL active-comparator (timolol) twice daily. The patient population studied had a mean age of 65±10 years. Seven percent of patients withdrew before the 6-month endpoint. Table 1: Ocular Adverse Reactions and Ocular Signs/Symptoms Reported by 5-15% of Patients Receiving Latanoprost Symptom/Finding Adverse Reactions (incidence (%)) Latanoprost (n=460) Timolol (n=369) Foreign body sensation 13 8 Punctate keratitis 10 9 Stinging 9 12 Conjunctival hyperemia 8 3 Blurred vision 8 8 Itching 8 8 Burning 7 8 Increased pigmentation of the Iris 7 0 Less than 1% of the patients treated with latanoprost ophthalmic solution required discontinuation of therapy because of intolerance to conjunctival hyperemia. Table 2: Adverse Reactions That Were Reported in 1-5% of Patients Receiving Latanoprost Adverse Reactions (incidence (%)) Latanoprost (n=460) Timolol (n=369) Ocular Events/Signs and Symptoms Excessive tearing 4 6 Eyelid discomfort/pain 4 2 Dry eye 3 3 Eye pain 3 3 Eyelid margin crusting 3 3 Erythema of the eyelid 3 2 Photophobia 2 1 Eyelid edema 1 3 Blepharitis 1 3 Systemic Events Upper respiratory tract infection/nasopharyngitis/influenza 3 3 Myalgia/arthralgia/back pain 1 0.5 Rash/allergic skin reaction 1 0.3 6.2 Postmarketing Experience The following reactions have been identified during postmarketing use of latanoprost ophthalmic solution in clinical practice. Because they are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to latanoprost, or a combination of these factors, include: Nervous System Disorders : Dizziness; headache; toxic epidermal necrolysis Eye Disorders : Eyelash and vellus hair changes of the eyelid (increased length, thickness, pigmentation, and number of eyelashes); keratitis; corneal edema and erosions; intraocular inflammation (iritis/uveitis); macular edema, including cystoid macular edema; trichiasis; periorbital and lid changes resulting in deepening of the eyelid sulcus; iris cyst; eyelid skin darkening; localized skin reaction on the eyelids; conjunctivitis; pseudopemphigoid of the ocular conjunctiva. Respiratory, Thoracic and Mediastinal Disorders : Asthma and exacerbation of asthma; dyspnea Gastrointestinal Disorders : Nausea; vomiting Skin and Subcutaneous Tissue Disorders : Pruritis Infections and Infestations : Herpes keratitis Cardiac Disorders : Angina; palpitations; angina unstable General Disorders and Administration Site Conditions : Chest pain"],"contraindications":["4 CONTRAINDICATIONS Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. Known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. (4)"],"labor_and_delivery":["8.2 Lactation Risk Summary It is not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when latanoprost ophthalmic solution is administered to a nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for latanoprost ophthalmic solution and any potential adverse effects on the breastfed child from latanoprost ophthalmic solution."],"mechanism_of_action":["12.1 Mechanism of Action Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. 12.2 Pharmacodynamics Reduction of the IOP in man starts about 3-4 hours after administration and maximum effect is reached after 8-12 hours. IOP reduction is present for at least 24 hours. 12.3 Pharmacokinetics Absorption Latanoprost is absorbed through the cornea where the isopropyl ester prodrug is hydrolyzed to the acid form to become biologically active. Distribution The distribution volume in humans is 0.16 ± 0.02 L/kg. The acid of latanoprost can be measured in aqueous humor during the first 4 hours, and in plasma only during the first hour after local administration. Studies in man indicate that the peak concentration in the aqueous humor is reached about two hours after topical administration. Elimination Metabolism Latanoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to the biologically active acid. The active acid of latanoprost reaching the systemic circulation is primarily metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites via fatty acid β-oxidation. Excretion The elimination of the acid of latanoprost from human plasma is rapid (t 1/2 = 17 min) after both IV and topical administration. Systemic clearance is approximately 7 mL/min/kg. Following hepatic β-oxidation, the metabolites are mainly eliminated via the kidneys. Approximately 88% and 98% of the administered dose are recovered in the urine after topical and IV dosing, respectively."],"indications_and_usage":["1 INDICATIONS AND USAGE Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprost ophthalmic solution is a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. (1)"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Pigmentation : Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation likely to be permanent. (5.1) Eyelash Changes : Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible. (5.2) 5.1 Pigmentation Latanoprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as latanoprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of latanoprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. Beyond 5 years the effects of increased pigmentation are not known [see Clinical Studies (14.2) ] . Iris color change may not be noticeable for several months to years. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery of the iris and the entire iris or parts of the iris become more brownish. Neither nevi nor freckles of the iris appear to be affected by treatment. While treatment with latanoprost ophthalmic solution can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly. 5.2 Eyelash Changes Latanoprost ophthalmic solution may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, the number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are usually reversible upon discontinuation of treatment. 5.3 Intraocular Inflammation Latanoprost ophthalmic solution should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation because inflammation may be exacerbated. 5.4 Macular Edema Macular edema, including cystoid macular edema, has been reported during treatment with latanoprost ophthalmic solution. Latanoprost ophthalmic solution should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. 5.5 Herpetic Keratitis Reactivation of herpes simplex keratitis has been reported during treatment with latanoprost ophthalmic solution. Latanoprost ophthalmic solution should be used with caution in patients with a history of herpetic keratitis. Latanoprost ophthalmic solution should be avoided in cases of active herpes simplex keratitis because inflammation may be exacerbated. 5.6 Bacterial Keratitis There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. 5.7 Contact Lens Use Latanoprost ophthalmic solution contains benzalkonium chloride, which may be absorbed by contact lenses. Contact lenses should be removed prior to the administration of latanoprost ophthalmic solution, and may be reinserted 15 minutes after administration."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Latanoprost was not carcinogenic in either mice or rats when administered by oral gavage at doses of up to 170 mcg/kg/day (approximately 2800 times the recommended maximum human dose) for up to 20 and 24 months, respectively. Mutagenesis Latanoprost was not mutagenic in bacteria, in mouse lymphoma, or in mouse micronucleus tests. Chromosome aberrations were observed in vitro with human lymphocytes. Additional in vitro and in vivo studies on unscheduled DNA synthesis in rats were negative. Impairment of Fertility Latanoprost has not been found to have any effect on male or female fertility in rat studies at IV doses up to 250 mcg/kg/day (811 times the maximum RHOD, on a mg/m 2 basis, assuming 100% absorption)."],"adverse_reactions_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\"><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" align=\"justify\" valign=\"top\">  <content styleCode=\"bold\">Symptom/Finding</content> </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Adverse Reactions (incidence (%))</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Latanoprost (n=460)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Timolol (n=369)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Foreign body sensation </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">13 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">8 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Punctate keratitis </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">10 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">9 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Stinging </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">9 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">12 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Conjunctival hyperemia </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">8 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Blurred vision </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">8 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">8 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Itching </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">8 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">8 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Burning </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">7 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">8 </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Increased pigmentation of the Iris </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">7 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0 </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"640\"><colgroup><col width=\"52.03125%\"/><col width=\"24.375%\"/><col width=\"23.59375%\"/></colgroup><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" rowspan=\"2\" align=\"justify\" valign=\"top\">  </td><td styleCode=\"Rrule\" colspan=\"2\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Adverse Reactions (incidence (%))</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Latanoprost (n=460)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Timolol (n=369)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"><content styleCode=\"bold\">Ocular Events/Signs and Symptoms</content> </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"justify\" valign=\"top\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Excessive tearing </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">4 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">6 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Eyelid discomfort/pain </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">4 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">2 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Dry eye </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Eye pain </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Eyelid margin crusting </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Erythema of the eyelid </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">2 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Photophobia </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">2 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Eyelid edema </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Blepharitis </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">3 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\"><content styleCode=\"bold\">Systemic Events</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">  </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Upper respiratory tract infection/nasopharyngitis/influenza </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Myalgia/arthralgia/back pain </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.5 </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"justify\" valign=\"top\">Rash/allergic skin reaction </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.3 </td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Potential for Pigmentation Advise patients about the potential for increased brown pigmentation of the iris, which may be permanent. Inform patients about the possibility of eyelid skin darkening, which may be reversible after discontinuation of latanoprost ophthalmic solution [see Warnings and Precautions (5.1) ] . Potential for Eyelash Changes Inform patients of the possibility of eyelash and vellus hair changes in the treated eye during treatment with latanoprost ophthalmic solution. These changes may result in a disparity between eyes in length, thickness, pigmentation, number of eyelashes or vellus hairs, and/or direction of eyelash growth. Eyelash changes are usually reversible upon discontinuation of treatment. Handling the Container Instruct patients to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions [see Warnings and Precautions (5.6) ] . When to Seek Physician Advice Advise patients that if they develop an intercurrent ocular condition (e.g., trauma or infection) or have ocular surgery, or develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physician’s advice concerning the continued use of the multiple-dose container. Contact Lens Use Advise patients that latanoprost ophthalmic solution contains benzalkonium chloride, which may be absorbed by contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of latanoprost ophthalmic solution. Use with Other Ophthalmic Drugs Advise patients that if more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. If a Dose is Missed Advise patients that if one dose is missed, treatment should continue with the next dose as normal. Manufactured by: Gland Pharma Limited Hyderabad-502307, INDIA Revised: 07/2023"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose as normal. The dosage of latanoprost ophthalmic solution should not exceed once daily; the combined use of two or more prostaglandins, or prostaglandin analogs including latanoprost ophthalmic solution is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP. Reduction of the IOP starts approximately 3 to 4 hours after administration and the maximum effect is reached after 8 to 12 hours. Latanoprost ophthalmic solution may be used concomitantly with other topical ophthalmic drug products to lower IOP. In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost ophthalmic solution. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. Contact lenses should be removed prior to the administration of latanoprost ophthalmic solution, and may be reinserted 15 minutes after administration. One drop in the affected eye(s) once daily in the evening. (2)"],"spl_product_data_elements":["latanoprost latanoprost LATANOPROST LATANOPROST ACID BENZALKONIUM CHLORIDE SODIUM CHLORIDE SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE SODIUM PHOSPHATE, DIBASIC, ANHYDROUS"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Ophthalmic solution containing latanoprost 50 mcg/mL (0.005%). Ophthalmic solution containing latanoprost 50 mcg/mL (0.005%). (3)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of latanoprost ophthalmic solution administration in pregnant women.to inform drug-associated risks. In animal reproduction studies, intravenous (IV) administration of latanoprost to pregnant rabbits and rats throughout the period of organogenesis produced malformations, embryofetal lethality and spontaneous abortion at clinically relevant doses [see Data] . The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20% of clinically recognized pregnancies. Data Animal Data Embryofetal studies were conducted in pregnant rabbits administered latanoprost daily by IV injection on gestation days 6 through 18, to target the period of organogenesis. A no observed adverse effect level (NOAEL) was not established for rabbit developmental toxicity. Post-implantation loss due to late resorption was shown as doses ≥0.2 mcg/kg/day (equivalent to 1.3 times the maximum recommended human ophthalmic dose [RHOD], on a mg/m 2 basis, assuming 100% absorption). Spina bifida and abortion occurred at 5 mcg/kg/day (equivalent to 32 times the maximum RHOD). Total litter loss due to early resorption was observed at doses ≥50 mcg/kg/day (324 times the maximum RHOD). Transient signs of maternal toxicity were observed after IV dosing (increased breathing, muscle tremors, slight motor incoordination) at 300 mcg/kg/day (1946 times the maximum RHOD). No maternal toxicity was observed at doses up to 50 mcg/kg/day. Embryofetal studies were conducted in pregnant rats administered latanoprost daily by IV injection on gestation days 6 through 15, to target the period of organogenesis. A NOAEL for rat developmental toxicity was not established. Cleft palate was observed at 1 mcg/kg (equivalent to 3.2 times the maximum RHOD, on a mg/m 2 basis, assuming 100% absorption). Brain porencephalic cyst(s) were observed ≥50 mcg/kg (162 times the maximum RHOD). Skeletal anomalies were observed at 250 mcg/kg (811 times the maximum RHOD). No maternal toxicity was detectable at 250 mcg/kg/day. Prenatal and postnatal development was assessed in rats. Pregnant rats were administered latanoprost daily by IV injection from gestation day 15, through delivery, until weaning (lactation Day 21). No adverse effects on rat offspring were observed at doses up to 10 mcg/kg/day (32 times the maximum RHOD, on a mg/m 2 basis, assuming 100% absorption). At 100 mcg/kg/day (324 times the maximum RHOD), maternal deaths and pup mortality occurred. 8.2 Lactation Risk Summary It is not known whether this drug or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when latanoprost ophthalmic solution is administered to a nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for latanoprost ophthalmic solution and any potential adverse effects on the breastfed child from latanoprost ophthalmic solution. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Bottle Label : NDC 68083-609-01 Rx Only Latanoprost Ophthalmic Solution 0.005% 125 mcg/2.5 mL STERILE For eye use only Carton Label : NDC 68083-609-01 Rx Only Latanoprost Ophthalmic Solution 0.005% 125 mcg/2.5 mL* For eye use only One 2.5 mL Bottle STERILE latanoprost-spl-bottle-label latanoprost-spl-carton-label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Latanoprost was not carcinogenic in either mice or rats when administered by oral gavage at doses of up to 170 mcg/kg/day (approximately 2800 times the recommended maximum human dose) for up to 20 and 24 months, respectively. Mutagenesis Latanoprost was not mutagenic in bacteria, in mouse lymphoma, or in mouse micronucleus tests. Chromosome aberrations were observed in vitro with human lymphocytes. Additional in vitro and in vivo studies on unscheduled DNA synthesis in rats were negative. Impairment of Fertility Latanoprost has not been found to have any effect on male or female fertility in rat studies at IV doses up to 250 mcg/kg/day (811 times the maximum RHOD, on a mg/m 2 basis, assuming 100% absorption)."]},"tags":[{"label":"Prostaglandin Analog","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin F2-alpha receptor","category":"target"},{"label":"PTGFR","category":"gene"},{"label":"PTGER1","category":"gene"},{"label":"PTGER3","category":"gene"},{"label":"S01EE01","category":"atc"},{"label":"Ophthalmic","category":"route"},{"label":"Topical","category":"route"},{"label":"Solution","category":"form"},{"label":"Solution/ Drops","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Ocular hypertension","category":"indication"},{"label":"Open-angle glaucoma","category":"indication"},{"label":"Thea Pharma","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Ophthalmic Solutions","category":"pharmacology"},{"label":"Pharmaceutical Solutions","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"TREATMENT FAILURE","source":"FDA FAERS","actionTaken":"5915 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"3208 reports"},{"date":"","signal":"EYE IRRITATION","source":"FDA FAERS","actionTaken":"2442 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"2253 reports"},{"date":"","signal":"INTRAOCULAR PRESSURE INCREASED","source":"FDA FAERS","actionTaken":"1849 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"1783 reports"},{"date":"","signal":"EYE PAIN","source":"FDA FAERS","actionTaken":"1753 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1620 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"1615 reports"},{"date":"","signal":"VISION BLURRED","source":"FDA FAERS","actionTaken":"1601 reports"}],"commonSideEffects":[{"effect":"upper respiratory tract infection/cold/flu","drugRate":"4%","severity":"common","_validated":true},{"effect":"Chest pain/angina pectoris","drugRate":"2%","severity":"common","_validated":true},{"effect":"muscle/joint/back pain","drugRate":"2%","severity":"common","_validated":true},{"effect":"rash/ allergic skin reaction","drugRate":"2%","severity":"common","_validated":true}],"contraindications":["Aphakia","Conjunctivitis","Cystoid macular edema","Disorder of macula of retina","Iritis","Macular retinal edema","Pseudophakia","Uveitis"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies of latanoprost administration in pregnant women. The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 10 to 4%, and of miscarriage is 15 to 20% of clinically recognized pregnancies.","Geriatric use":"No overall differences in safety or effectiveness have been observed between elderly and younger patients.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Thea Pharma","patents":[{"applNo":"N216472","source":"FDA Orange Book","status":"Active","expires":"Jul 8, 2031","useCode":"U-446","territory":"US","drugProduct":true,"patentNumber":"8637054","drugSubstance":false},{"type":"Method of Use","number":"9539262","applicant":"SUN PHARMACEUTICAL INDUSTRIES LTD","territory":"US","tradeName":"XELPROS","expiryDate":"2028-10-15"},{"type":"Formulation","number":"9629852","applicant":"SUN PHARMACEUTICAL INDUSTRIES LTD","territory":"US","tradeName":"XELPROS","expiryDate":"2029-09-12"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.2423/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$447","description":"LATANOPROST 0.005% EYE DROPS","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LATANOPROST","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:13:24.393504+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:13:24.393383+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:13:30.626927+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:13:24.465019+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LATANOPROST","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:13:30.829682+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:23.210891+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:23.210912+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:23.210917+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:13:32.390648+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Prostanoid FP receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:13:31.860438+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1051/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:13:31.523542+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA218257","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:13:23.210920+00:00"}},"allNames":"xalatan","offLabel":[],"synonyms":["roclanda","latanoprost","xalatan","(15R)-Latanoprost","PhXA41"],"timeline":[{"date":"1996-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PHARMACIA AND UPJOHN to Thea Pharma"},{"date":"1996-06-05","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pharmacia And Upjohn)"},{"date":"2018-09-12","type":"positive","source":"FDA Orange Book","milestone":"Xelpros approved — 0.005%"},{"date":"2021-01-07","type":"positive","source":"DrugCentral","milestone":"EMA approval (Aerie Pharmaceuticals Ireland Limited)"},{"date":"2025-04-14","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 11 manufacturers approved"}],"aiSummary":"Xalatan (Latanoprost) is a prostaglandin analog used to treat ocular hypertension and open-angle glaucoma. It works by targeting the prostaglandin F2-alpha receptor, increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. Originally developed by Pharmacia and Upjohn, it is now owned by Thea Pharma. Xalatan is a small molecule modality, FDA-approved in 1996, and has multiple generic manufacturers. As an off-patent medication, it is widely available.","approvals":[{"date":"1996-06-05","orphan":false,"company":"PHARMACIA AND UPJOHN","regulator":"FDA"},{"date":"2021-01-07","orphan":false,"company":"AERIE PHARMACEUTICALS IRELAND LIMITED","regulator":"EMA"}],"brandName":"Xalatan","ecosystem":[{"indication":"Ocular hypertension","otherDrugs":[{"name":"betaxolol","slug":"betaxolol","company":"Alcon"},{"name":"bimatoprost","slug":"bimatoprost","company":""},{"name":"brimonidine","slug":"brimonidine","company":""},{"name":"brinzolamide","slug":"brinzolamide","company":"Alcon Pharms Ltd"}],"globalPrevalence":1280000000},{"indication":"Open-angle glaucoma","otherDrugs":[{"name":"acetazolamide","slug":"acetazolamide","company":"Teva Branded Pharm"},{"name":"apraclonidine","slug":"apraclonidine","company":"Alcon"},{"name":"betaxolol","slug":"betaxolol","company":"Alcon"},{"name":"bimatoprost","slug":"bimatoprost","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Prostaglandin F2-alpha receptor","novelty":"Follow-on","targets":[{"gene":"PTGFR","source":"DrugCentral","target":"Prostaglandin F2-alpha receptor","protein":"Prostaglandin F2-alpha receptor"},{"gene":"PTGER1","source":"DrugCentral","target":"Prostaglandin E2 receptor EP1 subtype","protein":"Prostaglandin E2 receptor EP1 subtype"},{"gene":"PTGER3","source":"DrugCentral","target":"Prostaglandin E2 receptor EP3 subtype","protein":"Prostaglandin E2 receptor EP3 subtype"}],"modality":"Small Molecule","drugClass":"Prostaglandin Analog [EPC]","explanation":"Mechanism of Action. Latanoprost is prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.","oneSentence":"Xalatan works by increasing the outflow of fluid from the eye, reducing pressure.","technicalDetail":"Xalatan (Latanoprost) is a selective FP receptor agonist, which increases the uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure."},"commercial":{"launchDate":"1996","_launchSource":"DrugCentral (FDA 1996-06-05, PHARMACIA AND UPJOHN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1551","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LATANOPROST","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LATANOPROST","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T14:59:27.544233","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:13:34.974762+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"bimatoprost","drugSlug":"bimatoprost","fdaApproval":"2001-03-16","patentExpiry":"Oct 31, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"travoprost","drugSlug":"travoprost","fdaApproval":"2001-03-16","patentExpiry":"Sep 20, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tafluprost","drugSlug":"tafluprost","fdaApproval":"2012-02-10","patentExpiry":"May 28, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"latanoprostene bunod","drugSlug":"latanoprostene-bunod","fdaApproval":"2017-11-02","patentExpiry":"Feb 21, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"netarsudil","drugSlug":"netarsudil","fdaApproval":"2017-12-18","patentExpiry":"Nov 10, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"latanoprost","indications":{"approved":[{"name":"Ocular hypertension","source":"DrugCentral","snomedId":4210003,"regulator":"FDA","usPrevalence":119900000,"globalPrevalence":1280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Open-angle glaucoma","source":"DrugCentral","snomedId":84494001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Thea Pharma","drugCategory":"established","labelChanges":[],"relatedDrugs":[{"drugId":"bimatoprost","brandName":"bimatoprost","genericName":"bimatoprost","approvalYear":"2001","relationship":"same-class"},{"drugId":"travoprost","brandName":"travoprost","genericName":"travoprost","approvalYear":"2001","relationship":"same-class"},{"drugId":"tafluprost","brandName":"tafluprost","genericName":"tafluprost","approvalYear":"2012","relationship":"same-class"},{"drugId":"latanoprostene-bunod","brandName":"latanoprostene bunod","genericName":"latanoprostene bunod","approvalYear":"2017","relationship":"same-class"},{"drugId":"netarsudil","brandName":"netarsudil","genericName":"netarsudil","approvalYear":"2017","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07325240","phase":"PHASE4","title":"24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-11-21","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":30,"completionDate":"2027-10"},{"nctId":"NCT07354516","phase":"PHASE2,PHASE3","title":"Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2026-03-18","conditions":["OAG - Open-Angle Glaucoma","OHT - Ocular Hypertension"],"enrollment":36,"completionDate":"2026-07-15"},{"nctId":"NCT06819046","phase":"","title":"Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment","status":"COMPLETED","sponsor":"Colorado Ophthalmology Associates PC","startDate":"2025-02-14","conditions":["Glaucoma"],"enrollment":70,"completionDate":"2025-12-17"},{"nctId":"NCT05850936","phase":"NA","title":"Effect of IOP Lowering on Progressive HM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-06-01","conditions":["High Myopia","Intraocular Pressure"],"enrollment":152,"completionDate":"2028-11-30"},{"nctId":"NCT07435012","phase":"PHASE3","title":"Androgenic Alopecia TH07 Clinical Trial","status":"RECRUITING","sponsor":"Triple Hair Inc","startDate":"2026-04","conditions":["Androgenic Alopecia"],"enrollment":420,"completionDate":"2028-04"},{"nctId":"NCT07465913","phase":"PHASE4","title":"Rocklatan vs Latanoprost Post-DSLT","status":"NOT_YET_RECRUITING","sponsor":"Eye Centers of Southeast Texas","startDate":"2026-05-06","conditions":["Glaucoma"],"enrollment":36,"completionDate":"2027-05-06"},{"nctId":"NCT04412096","phase":"PHASE4","title":"Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2020-11-23","conditions":["Glaucoma","OHT - Ocular Hypertension"],"enrollment":59,"completionDate":"2025-05-22"},{"nctId":"NCT07425535","phase":"EARLY_PHASE1","title":"Optic Nerve Head Strain in Non-glaucoma Subjects","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-03","conditions":["Glaucoma"],"enrollment":30,"completionDate":"2028-03-31"},{"nctId":"NCT07412587","phase":"NA","title":"Therapeutic Potential of Topical Latanoprost Acid in Hair Loss - Pilot, Proof-of-concept Study","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2015-07-08","conditions":["Androgenetic Alopecia (AGA)","Telogen Effluvium","Female Pattern Hair Loss, Androgenic Alopecia"],"enrollment":29,"completionDate":"2016-07-08"},{"nctId":"NCT07082816","phase":"PHASE3","title":"Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alcon Research","startDate":"2025-09-02","conditions":["Ocular Hypertension","Open Angle Glaucoma"],"enrollment":489,"completionDate":"2026-05"},{"nctId":"NCT07310719","phase":"NA","title":"A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital","status":"RECRUITING","sponsor":"Lagos State Health Service Commission","startDate":"2025-10-15","conditions":["Primary Open Angle Glaucoma or Ocular Hypertension"],"enrollment":138,"completionDate":"2026-11"},{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":["Glaucoma"],"enrollment":1500,"completionDate":"2026-06"},{"nctId":"NCT04060758","phase":"PHASE1","title":"Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma","status":"COMPLETED","sponsor":"PolyActiva Pty Ltd","startDate":"2020-03-11","conditions":["Open Angle Glaucoma"],"enrollment":37,"completionDate":"2025-05-13"},{"nctId":"NCT07209410","phase":"PHASE4","title":"Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma","status":"RECRUITING","sponsor":"Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,","startDate":"2025-11-01","conditions":["Glaucoma"],"enrollment":35,"completionDate":"2027-06-01"},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":426,"completionDate":"2025-11-14"},{"nctId":"NCT06449352","phase":"PHASE4","title":"Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost","status":"COMPLETED","sponsor":"Westlake Eye Specialists","startDate":"2024-06-13","conditions":["Normal Tension Glaucoma"],"enrollment":100,"completionDate":"2025-09-22"},{"nctId":"NCT04500574","phase":"PHASE1","title":"Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2024-04-03","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":1,"completionDate":"2025-10-10"},{"nctId":"NCT06993597","phase":"","title":"Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-09-01","conditions":["Glaucoma"],"enrollment":60,"completionDate":"2026-06"},{"nctId":"NCT04630808","phase":"PHASE3","title":"MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2020-11-09","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":696,"completionDate":"2025-06-25"},{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":["Glaucoma"],"enrollment":28,"completionDate":"2024-10-04"},{"nctId":"NCT07048886","phase":"PHASE4","title":"Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Center for Sight Las Vegas","startDate":"2025-07-15","conditions":["Primary Open Angle Glaucoma"],"enrollment":68,"completionDate":"2026-12-31"},{"nctId":"NCT04445519","phase":"PHASE3","title":"Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2020-06-01","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":691,"completionDate":"2022-09-16"},{"nctId":"NCT06964191","phase":"PHASE2","title":"Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"PolyActiva Pty Ltd","startDate":"2025-05-31","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":75,"completionDate":"2026-11-15"},{"nctId":"NCT07016113","phase":"PHASE2","title":"0.005% Latanoprost Gel for Nonsegmental Vitiligo","status":"NOT_YET_RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2025-07-01","conditions":["Vitiligo - Macular Depigmentation"],"enrollment":10,"completionDate":"2025-11-30"},{"nctId":"NCT06960629","phase":"","title":"The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":["Pseudophakic Bullous Keratopathy","Glaucoma"],"enrollment":50,"completionDate":"2026-10-01"},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":["Open Angle Glaucoma"],"enrollment":70,"completionDate":"2026-04-01"},{"nctId":"NCT05583474","phase":"PHASE3","title":"OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2022-09-27","conditions":["Open Angle Glaucoma or Ocular Hypertension"],"enrollment":204,"completionDate":"2024-12-26"},{"nctId":"NCT06666855","phase":"PHASE3","title":"A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China","status":"RECRUITING","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2024-11-28","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":338,"completionDate":"2026-03-31"},{"nctId":"NCT06407973","phase":"PHASE4","title":"A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma","status":"TERMINATED","sponsor":"Sight Sciences, Inc.","startDate":"2024-08-21","conditions":["Primary Open Angle Glaucoma"],"enrollment":2,"completionDate":"2025-01-20"},{"nctId":"NCT05935527","phase":"PHASE1","title":"Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon","status":"COMPLETED","sponsor":"Peregrine Ophthalmic","startDate":"2023-04-28","conditions":["Lower Eyelid Steatoblepharon"],"enrollment":50,"completionDate":"2024-11-18"},{"nctId":"NCT06249152","phase":"PHASE2","title":"Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2024-04-21","conditions":["Open-angle Glaucoma (OAG)","Ocular Hypertension (OHT)","Glaucoma"],"enrollment":36,"completionDate":"2024-12-20"},{"nctId":"NCT06730516","phase":"EARLY_PHASE1","title":"Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2024-06-24","conditions":["Glaucoma"],"enrollment":56,"completionDate":"2024-10-01"},{"nctId":"NCT06629129","phase":"PHASE1","title":"Effect of Latanoprost on Optic Nerve Perfusion","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2024-06-24","conditions":["Treatment Outcome"],"enrollment":46,"completionDate":"2024-08-30"},{"nctId":"NCT06369077","phase":"PHASE4","title":"How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?","status":"TERMINATED","sponsor":"CT Glaucoma Associates","startDate":"2024-04-22","conditions":["Glaucoma, Open-Angle","Glaucoma; Drugs"],"enrollment":36,"completionDate":"2024-07-30"},{"nctId":"NCT01704989","phase":"PHASE4","title":"The Laser in Pseudoexfoliation (LIP) Study","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2012-06","conditions":["Glaucoma"],"enrollment":0,"completionDate":"2012-06"},{"nctId":"NCT02801617","phase":"PHASE3","title":"Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2015-09","conditions":["Primary Open Angle Glaucoma","Ocular Hypertension"],"enrollment":116,"completionDate":"2017-07-19"},{"nctId":"NCT04133311","phase":"PHASE3","title":"A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-04-10","conditions":["Open-Angle Glaucoma or Ocular Hypertension","Ocular Surface Disease"],"enrollment":386,"completionDate":"2022-10-26"},{"nctId":"NCT04761705","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"SUSPENDED","sponsor":"JeniVision, Inc.","startDate":"2021-03-10","conditions":["Ocular Hypertension","Open Angle Glaucoma"],"enrollment":70,"completionDate":"2025-07"},{"nctId":"NCT06239324","phase":"PHASE1,PHASE2","title":"Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser","status":"RECRUITING","sponsor":"Egymedicalpedia","startDate":"2024-02-01","conditions":["Alopecia Areata"],"enrollment":70,"completionDate":"2024-05-01"},{"nctId":"NCT05333419","phase":"PHASE1","title":"Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.","status":"COMPLETED","sponsor":"PolyActiva Pty Ltd","startDate":"2022-03-04","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":1,"completionDate":"2023-09-30"},{"nctId":"NCT05283395","phase":"PHASE4","title":"Rocklatan® Evaluation","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-03-28","conditions":["Glaucoma"],"enrollment":136,"completionDate":"2023-03-22"},{"nctId":"NCT02981446","phase":"PHASE3","title":"A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2017-01","conditions":["Open Angle Glaucoma or Ocular Hypertension"],"enrollment":370,"completionDate":"2019-01"},{"nctId":"NCT00579969","phase":"PHASE2","title":"Comparison of Latanoprost Vs. Timolol","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2003-12","conditions":["Glaucoma"],"enrollment":30,"completionDate":"2008-10"},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":28,"completionDate":"2023-11-23"},{"nctId":"NCT05495061","phase":"PHASE3","title":"A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2022-08-09","conditions":["Primary Open Angle Glaucoma, Ocular Hypertension"],"enrollment":325,"completionDate":"2023-04-18"},{"nctId":"NCT04957329","phase":"PHASE4","title":"Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-09-01","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":28,"completionDate":"2026-12-31"},{"nctId":"NCT00572936","phase":"PHASE2","title":"Circadian Rhythms of Aqueous Humor Dynamics in Humans","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-03-13","conditions":["Glaucoma"],"enrollment":30,"completionDate":"2009-11-01"},{"nctId":"NCT03697811","phase":"PHASE3","title":"DE-117 Spectrum 5 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-27","conditions":["Primary Open-angle Glaucoma and Ocular Hypertension"],"enrollment":107,"completionDate":"2022-01-13"},{"nctId":"NCT04811326","phase":"PHASE4","title":"Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation","status":"UNKNOWN","sponsor":"Shaimaa Fawzy Abdel-rady Abdel-latif","startDate":"2021-01-13","conditions":["Non-segmental Vitiligo"],"enrollment":150,"completionDate":"2024-03-13"},{"nctId":"NCT05513924","phase":"PHASE2,PHASE3","title":"Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.","status":"COMPLETED","sponsor":"South Valley University","startDate":"2022-03-15","conditions":["Vitiligo"],"enrollment":40,"completionDate":"2022-12-01"},{"nctId":"NCT03657797","phase":"PHASE2","title":"Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2018-08-01","conditions":["Glaucoma, Open-Angle","Hypertension, Ocular"],"enrollment":656,"completionDate":"2019-08-23"},{"nctId":"NCT01191008","phase":"","title":"Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-10","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":661,"completionDate":"2015-05"},{"nctId":"NCT04405245","phase":"PHASE2","title":"Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2020-06-06","conditions":["Ocular Hypertension","Primary Open Angle Glaucoma"],"enrollment":194,"completionDate":"2020-11-05"},{"nctId":"NCT05864885","phase":"PHASE1","title":"Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia","status":"UNKNOWN","sponsor":"Aneira Pharma, Inc.","startDate":"2023-06-09","conditions":["Androgenetic Alopecia"],"enrollment":14,"completionDate":"2023-07-17"},{"nctId":"NCT05790941","phase":"EARLY_PHASE1","title":"Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation","status":"UNKNOWN","sponsor":"Aneira Pharma, Inc.","startDate":"2023-03-11","conditions":["Hypotrichosis"],"enrollment":12,"completionDate":"2023-06-30"},{"nctId":"NCT05606796","phase":"PHASE4","title":"Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.","status":"UNKNOWN","sponsor":"Uzoma Chinyei Joan","startDate":"2022-12","conditions":["Effect of Drug"],"enrollment":76,"completionDate":"2023-09"},{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":["Ocular Surface Disease","Primary Open Angle Glaucoma"],"enrollment":50,"completionDate":"2022-08-24"},{"nctId":"NCT05165290","phase":"PHASE3","title":"Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure","status":"UNKNOWN","sponsor":"TearClear Corp","startDate":"2021-11-29","conditions":["Elevated Intraocular Pressure"],"enrollment":300,"completionDate":"2022-09"},{"nctId":"NCT04296916","phase":"NA","title":"Effect of Lowering IOP in Glaucoma Suspects With HM","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-17","conditions":["Glaucoma, Suspect","High Myopia"],"enrollment":264,"completionDate":"2024-10"},{"nctId":"NCT02585375","phase":"PHASE4","title":"Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2015-09-17","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":70,"completionDate":"2023-09-02"},{"nctId":"NCT05299593","phase":"PHASE4","title":"24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.","status":"UNKNOWN","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2020-06-04","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":43,"completionDate":"2022-06-30"},{"nctId":"NCT05241938","phase":"NA","title":"PSLT Compared to Prostaglandin Analogue Eye Drops","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2021-09-01","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":75,"completionDate":"2022-12-20"},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":436,"completionDate":"2020-11-06"},{"nctId":"NCT03949244","phase":"PHASE4","title":"Nailfold Capillary Blood Flow With Latanoprost Bunod","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-08-15","conditions":["Glaucoma, Open-Angle"],"enrollment":47,"completionDate":"2020-10-01"},{"nctId":"NCT00383019","phase":"PHASE3","title":"A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-11-14","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":300,"completionDate":"2007-10-01"},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":["Open-angle Glaucoma"],"enrollment":0,"completionDate":"2024-06-30"},{"nctId":"NCT04896125","phase":"","title":"Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-10-02","conditions":["Glaucoma; Ocular Disorders (I.E. Caused by Ocular Disorders)"],"enrollment":300,"completionDate":"2022-08-31"},{"nctId":"NCT04891588","phase":"NA","title":"Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD","status":"UNKNOWN","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-03-08","conditions":["Primary Open-angle Glaucoma","Ocular Hypertension"],"enrollment":50,"completionDate":"2021-12-08"},{"nctId":"NCT00934089","phase":"PHASE2","title":"A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":31,"completionDate":"2010-06"},{"nctId":"NCT00572455","phase":"PHASE2","title":"Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-12-11","conditions":["Primary Open-Angle Glaucoma","Ocular Hypertension"],"enrollment":318,"completionDate":"2009-06-26"},{"nctId":"NCT00947661","phase":"PHASE3","title":"Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Sun Pharma Advanced Research Company Limited","startDate":"2010-07","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":578,"completionDate":"2012-05"},{"nctId":"NCT00486252","phase":"","title":"Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-06","conditions":["Glaucoma,Open-Angle","Ocular Hypertension"],"enrollment":996,"completionDate":"2008-01"},{"nctId":"NCT01209624","phase":"","title":"Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-08","conditions":["Low Tension Glaucoma"],"enrollment":902,"completionDate":"2009-09"},{"nctId":"NCT00950690","phase":"","title":"Efficacy and Tolerability of Xalatan in Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":1289,"completionDate":"2007-12"},{"nctId":"NCT00159653","phase":"PHASE3","title":"A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":500,"completionDate":"2007-06"},{"nctId":"NCT00143208","phase":"PHASE4","title":"Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-05","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":250,"completionDate":"2006-04"},{"nctId":"NCT00856622","phase":"PHASE3","title":"A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-08","conditions":["Ocular Hypertension","Glaucoma","Open-angle Glaucoma"],"enrollment":436,"completionDate":"1999-06"},{"nctId":"NCT00230763","phase":"PHASE3","title":"Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-09","conditions":["Glaucoma, Primary Open Angle (POAG)","Ocular Hypertension"],"enrollment":396,"completionDate":"2007-10"},{"nctId":"NCT00277498","phase":"PHASE3","title":"A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-12","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":528,"completionDate":"2007-06"},{"nctId":"NCT00800267","phase":"PHASE3","title":"A Study of Glaucoma or Ocular Hypertension in Patients Within the United States","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-07","conditions":["Ocular Hypertension","Glaucoma"],"enrollment":418,"completionDate":"1999-06"},{"nctId":"NCT00140049","phase":"PHASE4","title":"A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":["Glaucoma, Open Angle","Ocular Hypertension"],"enrollment":238,"completionDate":"2006-07"},{"nctId":"NCT00219596","phase":"PHASE3","title":"Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-06","conditions":["Glaucoma, Open Angle","Ocular Hypertension"],"enrollment":240,"completionDate":"2006-09"},{"nctId":"NCT04743622","phase":"PHASE4","title":"Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost","status":"COMPLETED","sponsor":"CHA University","startDate":"2019-04-30","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":57,"completionDate":"2020-09-13"},{"nctId":"NCT04737928","phase":"NA","title":"Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2018-04-02","conditions":["Glaucoma, Primary Open Angle"],"enrollment":1,"completionDate":"2019-01-22"},{"nctId":"NCT00716859","phase":"PHASE3","title":"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-07","conditions":["Glaucoma"],"enrollment":139,"completionDate":"2009-11"},{"nctId":"NCT01265719","phase":"","title":"Long-Term Non-Interventional Latanoprost Study","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-12","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":175,"completionDate":"2016-02"},{"nctId":"NCT00847483","phase":"PHASE4","title":"Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-01","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":375,"completionDate":"2002-08"},{"nctId":"NCT00638742","phase":"PHASE1","title":"A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-05","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":47,"completionDate":"2009-03"},{"nctId":"NCT00647101","phase":"PHASE4","title":"A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-12","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":600,"completionDate":"2005-02"},{"nctId":"NCT01379144","phase":"PHASE2","title":"A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-01","conditions":["Primary Open Angle Glaucoma","Ocular Hypertension"],"enrollment":282,"completionDate":"2003-04"},{"nctId":"NCT00751062","phase":"PHASE3","title":"A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1992-11","conditions":["Open Angle Glaucoma","Ocular Hypertension"],"enrollment":267,"completionDate":"1993-12"},{"nctId":"NCT00143429","phase":"PHASE2","title":"Corneal Versus Conjunctival Delivery Using a Delivery Device","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":0,"completionDate":""},{"nctId":"NCT00751049","phase":"PHASE3","title":"A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1992-12","conditions":["Ocular Hypertension","Open Angle Glaucoma"],"enrollment":294,"completionDate":"1993-12"},{"nctId":"NCT00283764","phase":"PHASE3","title":"Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"","conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"enrollment":0,"completionDate":""},{"nctId":"NCT00846989","phase":"PHASE1,PHASE2","title":"Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-01","conditions":["Glaucoma","Ocular Hypertension"],"enrollment":276,"completionDate":"2009-04"},{"nctId":"NCT00397241","phase":"PHASE4","title":"24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-09","conditions":["Open-angle Glaucoma"],"enrollment":33,"completionDate":"2007-12"},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":["Glaucoma","Ocular Surface Disease"],"enrollment":43,"completionDate":"2016-01"},{"nctId":"NCT01281020","phase":"","title":"Adherence With Fixed Versus Unfixed Glaucoma Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-05","conditions":["Primary Open-angle Glaucoma","Ocular Hypertension","Exfoliation Glaucoma"],"enrollment":132,"completionDate":"2011-07"},{"nctId":"NCT03612817","phase":"PHASE4","title":"Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2017-01","conditions":["Glaucoma, Open-Angle"],"enrollment":42,"completionDate":"2018-07"},{"nctId":"NCT00757835","phase":"PHASE4","title":"24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2008-05","conditions":["Glaucoma"],"enrollment":40,"completionDate":"2009-03"}],"_emaApprovals":[{"date":"2021-01-07","status":"Authorised","company":"AERIE PHARMACEUTICALS IRELAND LIMITED"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic","formulation":"Solution, Solution/ Drops","formulations":[{"form":"SOLUTION","route":"OPHTHALMIC","productName":"LATANOPROST"},{"form":"SOLUTION","route":"OPHTHALMIC","productName":"Latanoprost"},{"form":"SOLUTION","route":"OPHTHALMIC","productName":"Xalatan"},{"form":"SOLUTION","route":"OPHTHALMIC","productName":"Latanoprost"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"LATANOPROST"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Latanoprost"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Rocklatan"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"XELPROS"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Latanoprost PF"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Tim-Brim-Dor-Lat"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Tim-Dor-Lat"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Tim-Lat -PF"},{"form":"SOLUTION/ DROPS","route":"TOPICAL","productName":"IYUZEH"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148440","MMSL":"4959","NDDF":"006059","UNII":"6Z5B6HVF6O","VUID":"4020967","CHEBI":"CHEBI:6384","VANDF":"4020967","INN_ID":"6980","RXNORM":"153159","UMLSCUI":"C0090306","chemblId":"CHEMBL1051","ChEMBL_ID":"CHEMBL1051","KEGG_DRUG":"D00356","DRUGBANK_ID":"DB00654","PUBCHEM_CID":"5311221","SNOMEDCT_US":"108838001","SECONDARY_CAS_RN":"41639-83-2","MESH_DESCRIPTOR_UI":"D000077338"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1996-","companyName":"Pharmacia And Upjohn","relationship":"Original Developer"},{"period":"present","companyName":"Thea Pharma","relationship":"Current Owner"},{"period":"2021","companyName":"Aerie Pharmaceuticals Ireland Limited","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.28 hours","clearance":"6.7 mL/min/kg","fractionUnbound":"0.1%"},"publicationCount":2181,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"S01EE01","allCodes":["S01EE01","S01EE51"]},"biosimilarFilings":[],"originalDeveloper":"Pharmacia And Upjohn","recentPublications":[{"date":"2026 Jun","pmid":"41890785","title":"Using selective laser trabeculoplasty to manage glaucoma in a child with phakomatosis pigmentovascularis.","journal":"American journal of ophthalmology case reports"},{"date":"2026 Apr","pmid":"41883732","title":"Preclinical Evaluation of Safety and Efficacy of QLS-111: A Novel Formulation of an Adenosine Triphosphate-Sensitive Potassium Channel Opener.","journal":"Ophthalmology science"},{"date":"2026","pmid":"41868229","title":"Sustained intraocular pressure lowering from suprachoroidal injection of a latanoprost lipid nanoparticle delivery system in the rabbit.","journal":"Frontiers in medicine"},{"date":"2026 Feb 13","pmid":"41842582","title":"Efficacy and Safety of Preservative-Free versus Preserved Latanoprost in Glaucoma and Ocular Hypertension: A Systematic Review and Meta-analysis.","journal":"Journal of glaucoma"},{"date":"2026 Mar 7","pmid":"41794792","title":"Mitochondria transplantation reduces intraocular pressure by improving mitochondrial function and remodeling trabecular meshwork.","journal":"Journal of translational medicine"}],"combinationProducts":[{"brandName":"Rocklatan","ingredients":"latanoprost + netarsudil"}],"companionDiagnostics":[],"genericManufacturers":12,"_genericFilersChecked":true,"genericManufacturerList":["Amring Pharms","Apotex Inc","Bausch And Lomb","Carnegie","Epic Pharma Llc","Eugia Pharma","Fdc Ltd","Gland","Mankind Pharma","Micro Labs","Sandoz","Somerset"],"status":"approved","companyName":"Thea Pharma","companyId":"thea-pharma","modality":"Small molecule","firstApprovalDate":"1996","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-06-05T00:00:00.000Z","mah":"PHARMACIA AND UPJOHN","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":11,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:13:34.974762+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}